Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

Cited In for PubMed (Select 14630803)

1.

The use of MAGE C1 and flow cytometry to determine the malignant cell type in multiple myeloma.

Wienand K, Shires K.

PLoS One. 2015 Mar 20;10(3):e0120734. doi: 10.1371/journal.pone.0120734. eCollection 2015.

2.

Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma.

Hansmann L, Blum L, Ju CH, Liedtke M, Robinson WH, Davis MM.

Cancer Immunol Res. 2015 Jun;3(6):650-60. doi: 10.1158/2326-6066.CIR-14-0236-T. Epub 2015 Feb 20.

PMID:
25711758
3.

Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells.

Báez A, Piruat JI, Caballero-Velázquez T, Sánchez-Abarca LI, Álvarez-Laderas I, Barbado MV, García-Guerrero E, Millán-Uclés Á, Martín-Sánchez J, Medrano M, Pérez-Simón JA.

Am J Cancer Res. 2014 Dec 15;5(1):386-95. eCollection 2015.

4.

In vivo molecular imaging of cancer stem cells.

Heryanto YD, Achmad A, Taketomi-Takahashi A, Tsushima Y.

Am J Nucl Med Mol Imaging. 2014 Dec 15;5(1):14-26. eCollection 2015. Review.

5.

Identify multiple myeloma stem cells: Utopia?

Saltarella I, Lamanuzzi A, Reale A, Vacca A, Ria R.

World J Stem Cells. 2015 Jan 26;7(1):84-95. doi: 10.4252/wjsc.v7.i1.84. Review.

6.

CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.

Wu D, Guo X, Su J, Chen R, Berenzon D, Guthold M, Bonin K, Zhao W, Zhou X.

Biochim Biophys Acta. 2015 Feb;1853(2):338-47. doi: 10.1016/j.bbamcr.2014.11.019. Epub 2014 Nov 21.

PMID:
25450979
7.

The development of potential antibody-based therapies for myeloma.

Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B.

Blood Rev. 2015 Mar;29(2):81-91. doi: 10.1016/j.blre.2014.09.011. Epub 2014 Sep 28.

8.

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma.

Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F.

Oncotarget. 2014 Dec 15;5(23):11986-97.

9.

Implications of heterogeneity in multiple myeloma.

de Mel S, Lim SH, Tung ML, Chng WJ.

Biomed Res Int. 2014;2014:232546. doi: 10.1155/2014/232546. Epub 2014 Jul 2. Review.

10.

Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.

Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT.

Haematologica. 2014 Aug;99(8):1277-84. doi: 10.3324/haematol.2013.085209. Review.

11.

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma.

Lien IC, Horng LY, Hsu PL, Wu CL, Sung HC, Wu RT.

Genes Cancer. 2014 Mar;5(3-4):127-41.

12.

Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.

Wen J, Tao W, Kuiatse I, Lin P, Feng Y, Jones RJ, Orlowski RZ, Zu Y.

Int J Cancer. 2015 Mar 1;136(5):991-1002. doi: 10.1002/ijc.29078. Epub 2014 Jul 23.

PMID:
25042852
13.

MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells.

Brower JV, Clark PA, Lyon W, Kuo JS.

Neurochem Int. 2014 Nov;77:68-77. doi: 10.1016/j.neuint.2014.06.002. Epub 2014 Jun 14. Review.

PMID:
24937770
14.

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S.

Immunol Res. 2014 Aug;59(1-3):188-202. doi: 10.1007/s12026-014-8528-x. Review.

PMID:
24845460
15.

Activation of liver X receptors inhibits hedgehog signaling, clonogenic growth, and self-renewal in multiple myeloma.

Agarwal JR, Wang Q, Tanno T, Rasheed Z, Merchant A, Ghosh N, Borrello I, Huff CA, Parhami F, Matsui W.

Mol Cancer Ther. 2014 Jul;13(7):1873-81. doi: 10.1158/1535-7163.MCT-13-0997. Epub 2014 May 7.

16.

Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells.

Medina DJ, Abass-Shereef J, Walton K, Goodell L, Aviv H, Strair RK, Budak-Alpdogan T.

PLoS One. 2014 Apr 10;9(4):e91042. doi: 10.1371/journal.pone.0091042. eCollection 2014.

17.

Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.

Paíno T, Sarasquete ME, Paiva B, Krzeminski P, San-Segundo L, Corchete LA, Redondo A, Garayoa M, García-Sanz R, Gutiérrez NC, Ocio EM, San-Miguel JF.

PLoS One. 2014 Mar 21;9(3):e92378. doi: 10.1371/journal.pone.0092378. eCollection 2014.

18.

Cervical cancer cells with positive Sox2 expression exhibit the properties of cancer stem cells.

Liu XF, Yang WT, Xu R, Liu JT, Zheng PS.

PLoS One. 2014 Jan 28;9(1):e87092. doi: 10.1371/journal.pone.0087092. eCollection 2014.

19.

Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.

Su J, Zhang L, Zhang W, Choi DS, Wen J, Jiang B, Chang CC, Zhou X.

PLoS One. 2014 Jan 27;9(1):e85059. doi: 10.1371/journal.pone.0085059. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e112421.

20.

Osteoblastic niche supports the growth of quiescent multiple myeloma cells.

Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N.

Blood. 2014 Apr 3;123(14):2204-8. doi: 10.1182/blood-2013-07-517136. Epub 2014 Jan 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk